View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorized
June 15, 2020

Results from study show oral selexipag for pulmonary arterial hypertension effective and safe in children

By Victoria Smith

An observational study published in the Journal of Heart and Lung Transplantation in April revealed that Actelion’s oral Uptravi (selexipag) is safe and well-tolerated in children with pulmonary arterial hypertension when administered as an add-on treatment. Selexipag is currently the only prostacyclin receptor agonist approved to target the prostacyclin pathway in adults with pulmonary arterial hypertension.

According to GlobalData, youths under age 18 years had a higher number of adjusted incident cases of pulmonary arterial hypertension in the six major markets in 2019 compared to the 18–19 years old age group. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology